Literature DB >> 2350209

Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine 18]-fluorodeoxyglucose.

E D London1, N G Cascella, D F Wong, R L Phillips, R F Dannals, J M Links, R Herning, R Grayson, J H Jaffe, H N Wagner.   

Abstract

We examined the effects of cocaine hydrochloride (40 mg intravenously) on regional cerebral metabolic rates for glucose and on subjective self-reports of eight polydrug abusers in a double-blind, placebo-controlled, crossover study. The regional cerebral metabolic rate for glucose was measured by the [fluorine 18]-fluorodeoxyglucose method, using positron emission tomography. With eyes covered, subjects listened to a tape that presented white noise, "beep" prompts, and questions about subjective effects of cocaine or saline. Cocaine produced euphoria and reduced glucose utilization globally (mean reduction, 14%). Twenty-six of 29 brain regions (all neocortical areas, basal ganglia, portions of the hippocampal formation, thalamus, and midbrain) showed significant decrements (5% to 26%) in the regional cerebral metabolic rate for glucose. No significant effects of cocaine were observed in the pons, the cerebellar cortex, or the vermis. Right-greater-than-left hemispheric asymmetry of regional cerebral metabolic rates for glucose occurred in the lateral thalamus. The findings demonstrate that reduced cerebral metabolism is associated with cocaine-induced euphoria.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2350209     DOI: 10.1001/archpsyc.1990.01810180067010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  59 in total

1.  Impact of self-administered cocaine and cocaine cues on extracellular dopamine in mesolimbic and sensorimotor striatum in rhesus monkeys.

Authors:  C W Bradberry; R L Barrett-Larimore; P Jatlow; S R Rubino
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

2.  Acute and chronic dopamine dynamics in a nonhuman primate model of recreational cocaine use.

Authors:  C W Bradberry
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

Review 3.  Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex.

Authors:  Rita Z Goldstein; Nora D Volkow
Journal:  Am J Psychiatry       Date:  2002-10       Impact factor: 18.112

Review 4.  Neuroimaging in drug abuse.

Authors:  Kimberly P Lindsey; S John Gatley; Nora D Volkow
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

Review 5.  [Neuroimaging in substance abuse disorders].

Authors:  A de Mendelssohn; S Kasper; J Tauscher
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

6.  The behavioral economics of will in recovery from addiction.

Authors:  John Monterosso; George Ainslie
Journal:  Drug Alcohol Depend       Date:  2006-10-10       Impact factor: 4.492

7.  Beer flavor provokes striatal dopamine release in male drinkers: mediation by family history of alcoholism.

Authors:  Brandon G Oberlin; Mario Dzemidzic; Stella M Tran; Christina M Soeurt; Daniel S Albrecht; Karmen K Yoder; David A Kareken
Journal:  Neuropsychopharmacology       Date:  2013-04-15       Impact factor: 7.853

Review 8.  PET studies in nonhuman primate models of cocaine abuse: translational research related to vulnerability and neuroadaptations.

Authors:  Robert W Gould; Angela N Duke; Michael A Nader
Journal:  Neuropharmacology       Date:  2013-02-28       Impact factor: 5.250

Review 9.  Nonhuman primate neuroimaging and the neurobiology of psychostimulant addiction.

Authors:  Leonard L Howell; Kevin S Murnane
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

10.  Cocaine is pharmacologically active in the nonhuman primate fetal brain.

Authors:  Helene Benveniste; Joanna S Fowler; William D Rooney; Bruce A Scharf; W Walter Backus; Igor Izrailtyan; Gitte M Knudsen; Steen G Hasselbalch; Nora D Volkow
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.